# Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

> **NCT04078191** · PHASE2 · TERMINATED · sponsor: **Navidea Biopharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tc 99m tilmanocept

## Key facts

- **NCT ID:** NCT04078191
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-14
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-09
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04078191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04078191, "Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04078191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*